Cargando…

Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population

Background: This study aims to investigate the extent of the BNT162b2 mRNA vaccine-induced antibodies against SARS-CoV-2 in a large cohort of Italian subjects belonging to the early vaccinated cohort in Italy. Methods: A prospective study was conducted between December 2020 and May 2021. Three blood...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadopoli, Rosa, De Sarro, Caterina, Palleria, Caterina, Gallelli, Luca, Pileggi, Claudia, De Sarro, Giovambattista
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705669/
https://www.ncbi.nlm.nih.gov/pubmed/34960240
http://dx.doi.org/10.3390/vaccines9121494
_version_ 1784622003829866496
author Papadopoli, Rosa
De Sarro, Caterina
Palleria, Caterina
Gallelli, Luca
Pileggi, Claudia
De Sarro, Giovambattista
author_facet Papadopoli, Rosa
De Sarro, Caterina
Palleria, Caterina
Gallelli, Luca
Pileggi, Claudia
De Sarro, Giovambattista
author_sort Papadopoli, Rosa
collection PubMed
description Background: This study aims to investigate the extent of the BNT162b2 mRNA vaccine-induced antibodies against SARS-CoV-2 in a large cohort of Italian subjects belonging to the early vaccinated cohort in Italy. Methods: A prospective study was conducted between December 2020 and May 2021. Three blood samples were collected for each participant: one at the time of the first vaccine dose (T0), one at the time of the second vaccine dose, (T1) and the third 30 days after this last dose (T2). Results: We enrolled 2591 fully vaccinated subjects; 16.5% were frail subjects, and 9.8% were over 80 years old. Overall, 98.1% of subjects were seropositive when tested at T2, and 76.3% developed an anti-S IgG titer ≥4160 AU/mL, which is adequate to develop viral neutralizing antibodies. Seronegative subjects at T1 were more likely to remain seronegative at T2 or to develop a low–intermediate anti-S IgG titer (51–4159 AU/mL). Conclusions: In summary, vaccination leads to detectable anti-S IgG titer in nearly all vaccine recipients. Stratification of the seroconversion level could be useful to promptly identify high-risk groups who may not develop a viral neutralizing response, even in the presence of seroconversion, and therefore may remain at higher risk of infection, despite vaccination.
format Online
Article
Text
id pubmed-8705669
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87056692021-12-25 Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population Papadopoli, Rosa De Sarro, Caterina Palleria, Caterina Gallelli, Luca Pileggi, Claudia De Sarro, Giovambattista Vaccines (Basel) Article Background: This study aims to investigate the extent of the BNT162b2 mRNA vaccine-induced antibodies against SARS-CoV-2 in a large cohort of Italian subjects belonging to the early vaccinated cohort in Italy. Methods: A prospective study was conducted between December 2020 and May 2021. Three blood samples were collected for each participant: one at the time of the first vaccine dose (T0), one at the time of the second vaccine dose, (T1) and the third 30 days after this last dose (T2). Results: We enrolled 2591 fully vaccinated subjects; 16.5% were frail subjects, and 9.8% were over 80 years old. Overall, 98.1% of subjects were seropositive when tested at T2, and 76.3% developed an anti-S IgG titer ≥4160 AU/mL, which is adequate to develop viral neutralizing antibodies. Seronegative subjects at T1 were more likely to remain seronegative at T2 or to develop a low–intermediate anti-S IgG titer (51–4159 AU/mL). Conclusions: In summary, vaccination leads to detectable anti-S IgG titer in nearly all vaccine recipients. Stratification of the seroconversion level could be useful to promptly identify high-risk groups who may not develop a viral neutralizing response, even in the presence of seroconversion, and therefore may remain at higher risk of infection, despite vaccination. MDPI 2021-12-17 /pmc/articles/PMC8705669/ /pubmed/34960240 http://dx.doi.org/10.3390/vaccines9121494 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Papadopoli, Rosa
De Sarro, Caterina
Palleria, Caterina
Gallelli, Luca
Pileggi, Claudia
De Sarro, Giovambattista
Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population
title Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population
title_full Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population
title_fullStr Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population
title_full_unstemmed Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population
title_short Serological Response to SARS-CoV-2 Messenger RNA Vaccine: Real-World Evidence from Italian Adult Population
title_sort serological response to sars-cov-2 messenger rna vaccine: real-world evidence from italian adult population
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705669/
https://www.ncbi.nlm.nih.gov/pubmed/34960240
http://dx.doi.org/10.3390/vaccines9121494
work_keys_str_mv AT papadopolirosa serologicalresponsetosarscov2messengerrnavaccinerealworldevidencefromitalianadultpopulation
AT desarrocaterina serologicalresponsetosarscov2messengerrnavaccinerealworldevidencefromitalianadultpopulation
AT palleriacaterina serologicalresponsetosarscov2messengerrnavaccinerealworldevidencefromitalianadultpopulation
AT gallelliluca serologicalresponsetosarscov2messengerrnavaccinerealworldevidencefromitalianadultpopulation
AT pileggiclaudia serologicalresponsetosarscov2messengerrnavaccinerealworldevidencefromitalianadultpopulation
AT desarrogiovambattista serologicalresponsetosarscov2messengerrnavaccinerealworldevidencefromitalianadultpopulation